OBJECTIVES: To evaluate influenza and pneumococcal vaccine coverage in patients taking biological therapy for chronic inflammatory joint disease and to identify factors associated with the decision to administer these two vaccines. METHODS: Retrospective cross-sectional questionnaire study of a cohort of 584 patients taking biological therapy for chronic inflammatory joint disease (rheumatoid arthritis or spondyloarthritis). We studied the influenza and pneumococcal vaccine coverage rates, information about these vaccines given to patients by the primary-care physician and rheumatologist, and reasons for not administering the vaccines. RESULTS: Overall vaccine coverage rates were 44% for influenza and 62% for pneumococcus. Factors associated with being vaccinated were patient age, previous influenza vaccination, and patient information. Concern about adverse effects and absence of patient information by the primary-care physician and rheumatologist were associated with very low coverage rates. CONCLUSION: This study showed insufficient vaccine coverage rates, particularly against influenza, in a population at high risk because of exposure to biological therapy. Patient information by healthcare professionals about influenza and pneumococcal vaccination has a major impact and should be renewed as often as possible.
OBJECTIVES: To evaluate influenza and pneumococcal vaccine coverage in patients taking biological therapy for chronic inflammatory joint disease and to identify factors associated with the decision to administer these two vaccines. METHODS: Retrospective cross-sectional questionnaire study of a cohort of 584 patients taking biological therapy for chronic inflammatory joint disease (rheumatoid arthritis or spondyloarthritis). We studied the influenza and pneumococcal vaccine coverage rates, information about these vaccines given to patients by the primary-care physician and rheumatologist, and reasons for not administering the vaccines. RESULTS: Overall vaccine coverage rates were 44% for influenza and 62% for pneumococcus. Factors associated with being vaccinated were patient age, previous influenza vaccination, and patient information. Concern about adverse effects and absence of patient information by the primary-care physician and rheumatologist were associated with very low coverage rates. CONCLUSION: This study showed insufficient vaccine coverage rates, particularly against influenza, in a population at high risk because of exposure to biological therapy. Patient information by healthcare professionals about influenza and pneumococcal vaccination has a major impact and should be renewed as often as possible.
Authors: Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett Journal: ACR Open Rheumatol Date: 2022-03-29
Authors: Patricia Richi; Jose Yuste; Teresa Navío; Laura González-Hombrado; Marina Salido; Israel Thuissard-Vasallo; Ana Jiménez-Díaz; Jesús Llorente; Laura Cebrián; Leticia Lojo; Martina Steiner; Tatiana Cobo; María Dolores Martín; Marta García-Castro; Patricia Castro; Santiago Muñoz-Fernández Journal: Vaccines (Basel) Date: 2021-02-28
Authors: Gabriel Figueroa-Parra; Andrea Moreno-Salinas; Leticia Santoyo-Fexas; Carmen Magdalena Gamboa-Alonso; Juan Pablo Carrizales-Luna; Ivan de Jesus Hernandez-Galarza; Dionicio Angel Galarza-Delgado; Jorge Antonio Esquivel-Valerio Journal: Reumatologia Date: 2022-01-12
Authors: Gabriel Figueroa-Parra; Jorge Antonio Esquivel-Valerio; Leticia Santoyo-Fexas; Andrea Moreno-Salinas; Carmen Magdalena Gamboa-Alonso; Ana Laura De Leon-Ibarra; Dionicio Angel Galarza-Delgado Journal: Hum Vaccin Immunother Date: 2020-09-29 Impact factor: 3.452